ライフサイエンスコーパス: L-arginine

1 ic oxide synthase inhibitor (N(G)-monomethyl L-arginine).

2 itochondria isolated from rats or mice given L-arginine).

3 he, augment the ISCs function in response to L-arginine.

4 endothelial nitric oxide synthase substrate, L-arginine.

5 rical dimethylarginine (ADMA) and monomethyl-l-arginine.

6 bition witnessed when MPhis were cultured in L-arginine.

7 duct or by intraperitoneal administration of L-arginine.

8 form, indicating that the bacterium requires l-arginine.

9 , adenosine, cytosine, guanine, thymine, and l-arginine.

10 s, from physiologically abundant glucose and L-arginine.

11 ine dihydrolase pathway to generate ATP from L-arginine.

12 rating that protection from colitis requires l-arginine.

13 OS) and thus can catalyze NO production from L-arginine.

14 in mice after administration of cerulein or L-arginine.

15 ith the olfactory response to the amino acid L-arginine.

16 eloped sensor revealed a good selectivity to L-arginine.

17 he inverse of FBF reserve to N(G)-monomethyl-L-arginine.

18 ses (NOSs) catalyze the formation of NO from l-arginine.

19 ar, including l-asparagine, l-glutamine, and l-arginine.

20 , an enzyme that metabolizes l-citrulline to l-arginine.

21 iated by nitric oxide-dependent depletion of l-arginine.

22 ic hormone whose effects can be prevented by l-arginine.

23 -oxo mimic of the ferryl intermediate in the l-arginine 3-hydroxylase, VioC, reveals coordinated moti

24 vity was measured by using Nalpha-Benzoyl-D, l-arginine 4-nitroanilide hydrochloride (BAPNA) as the s

25 le compound (N2-[(2,2-diphenylethoxy)acetyl]-l-arginine, 4), known as a weak C3aR antagonist (IC50 mu

26 Bath application of SNAP (2mM) or l-arginine (50mM) elicited similar inhibitory effects on

27 (3), L-tryptophan (4), L-phenylalanine (5), L-arginine (6) has been accomplished by employing ZnCl2

28 tradermal microdialysis of l-N(G)-monomethyl-l-arginine, a nitric oxide antagonist, in response to in

29 Treatment of cells with N(G)-nitro-L-arginine, a slowly reversible competitive inhibitor th

30 c oxide synthase inhibitor l-N(G)-monomethyl-l-arginine acetate (l-NMMA) into both femoral arteries r

31 n improvement in eNOS activity and increased L-arginine/ADMA ratio and DDAH1 expression.

32 In addition, these lower L-arginine/ADMA ratios are associated with reduced lung

33 Also in this phenotype, a reduced L-arginine/ADMA was associated with less IgE, increased

34 The log of plasma L-arginine/ADMA was inversely correlated with BMI in the

35 he relationship was lost after adjusting for L-arginine/ADMA.

36 d the clinically compatible basic amino acid L-arginine against planktonic and biofilm bacteria both

37 In Escherichia coli, the l-arginine/agmatine antiporter AdiC facilitates the expo

38 ate binding and specificity of the wild-type l-arginine/agmatine antiporter AdiC.

39 lin D, encoded by Ppid) by administration of L-arginine (also in rats), caerulein, bile acid, or an A

40 abeling studies reveal that N(omega)-methoxy-L-arginine, an alternative NOS substrate, produces citru

41 Administration of L-arginine and a beta-adrenergic receptor agonist (CL316

42 the MmMNAGS-K in the presence and absence of L-arginine and a tetramer-octamer equilibrium that shift

43 Nonetheless, many nNOS inhibitors mimic l-arginine and are poorly bioavailable.

44 mum sized fluorescent capsules based on poly-L-arginine and dextran sulfate for targeting the kidney

45 consequential link between the transport of l-arginine and endothelial nitric oxide synthase uncoupl

46 omain electron transfer mechanism to oxidize l-arginine and generate NO.

47 scent strains, we studied the combination of L-arginine and gentamicin against planktonic persisters

48 in the vasculature can compete with eNOS for L-arginine and has been implicated in atherosclerosis.

49 Most nNOS inhibitors mimic l-arginine and have poor bioavailability.

50 s associated with reduced systemic levels of l-arginine and increased asymmetric dimethylarginine (AD

51 Substantial production of NH2Cl from l-arginine and l-histidine was observed at Cl/P = 1.0 an

52 as observed from UV254-irradiated samples of l-arginine and l-histidine when Cl/P = 2.0 and 3.0, as w

53 show that these proteins, which are rich in l-arginine and l-lysine amino acids, promote COM growth.

54 issociated into tetramers in the presence of l-arginine and NaCl, which was reversible upon dilution

55 , we explore the possible involvement of the L-arginine and nitric oxide (NO) pathway on RBC deformab

56 sachets/d) of either a formula enriched with l-arginine and omega-3 (n-3) fatty and ribonucleic acids

57 NO is synthesized from l-arginine and oxygen (O(2)) by the enzyme nitric oxide

58 xpressing nitric oxide synthase-2 (NOS2) via l-arginine and oxygen is a key protective mechanism agai

59 creased plasma levels of ADMA and monomethyl-l-arginine and reduced endothelial nitric oxide response

60 ester (L-NAME) pretreatment blocked, whereas L-arginine and sodium nitroprusside (SNP) each enhanced,

61 itric oxide (NO) donor (SNAP), NO substrate (l-arginine), and NO synthase inhibitor (l-NAME) on bladd

62 only the heating of a mixture of Ce(NO3 )3 , l-arginine, and preformed Pd seeds in water without addi

63 ith the interindividual variability in ADMA, l-arginine, and SDMA.

64 Treatment with gamma interferon (IFN-gamma), l-arginine, and tetrahydrobiopterin enhanced expression

65 VGSC was investigated by using substance P, l-arginine, and veratrine, respectively, as biomarkers.

66 ins (BaCl2, ouabain, L-NMMA [N(G)-monomethyl-L-arginine] and ketorolac, respectively).

67 parameters of pancreatic injury in mice with L-arginine AP.

68 method for the quantitative determination of L-arginine (Arg) has been developed.

69 Here, we show that L-arginine (Arg) uptake through the host cell's SLC7A2-e

70 OS was not affected by the concentrations of l-arginine (Arg), NADPH, FAD, FMN, tetrahydrobiopterin (

71 tive dimers by tetrahydrobiopterin (H4B) and l-arginine (Arg).

72 ry tonometry (EndoPAT), and plasma levels of l-arginine, arginase-1, and asymmetric dimethylarginine

73 L-Lysine (lysine), L-Cysteine (cysteine) and L-Arginine (arginine) as bifunctional species with (or w

74 dehydrogenase (PdhR), trehalose (TreR), and l-arginine (ArgR) repressor proteins were functionalized

75 of aminoglycoside and the non-toxic adjuvant L-arginine as catheter lock solution could constitute a

76 erium Pseudomonas putida KT2440, identifying L-arginine as the main one causing a significant increas

77 VKR can be activated by L-amino acids, with L-arginine as the most potent agonist.

78 Thus, an increased availability of l-arginine as well as altered intestinal microbiota and

79 These data suggest that increasing L-arginine bioavailability via oral supplementation can

80 d the L-arginine to ADMA ratio (a measure of L-arginine bioavailability) were reduced in patients wit

81 re vivax malaria, is associated with reduced L-arginine bioavailability, and may contribute to microv

82 se (NAGS-K) catalyzes the first two steps of L-arginine biosynthesis.

83 plants, NAG is the first intermediate of the L-arginine biosynthesis; in animals, NAG is an allosteri

84 Arginase-1 (Arg1) also metabolizes l-arginine but does not require oxygen as a substrate an

85 ive catalyst for the oxidation of endogenous L-arginine by hydrogen peroxide.

86 l-Citrulline is recycled to l-arginine by two enzymes, argininosuccinate synthase (A

87 Two L-arginine catalytic enzymes, iNOS and arginase 1, are w

88 N(G)-monomethyl L-arginine completely inhibited the increase in endothel

89 iggered by mixing a reduced enzyme/N-hydroxy-l-arginine complex with an aerated buffer solution.

90 tures of SmTK complexed with taurocyamine or l-arginine compounds explain the mechanism by which an a

91 n and activity and markedly elevated cardiac l-arginine concentrations, unmasking a novel mechanism o

92 Wnt3a in the Paneth cell niche by exogenous L-arginine couples ISCs function and favours a model in

93 replication without immunopathology, whilst L-arginine decreased.

94 Prevention or reversal of L-arginine deficiency blunts mastocytosis in ileal villi

95 parasite-infected mice, like humans, develop L-arginine deficiency, which is associated with intestin

96 of mice with the NOS inhibitor NG-monomethyl-l-arginine delayed weight loss and death among 1918 viru

97 vity, evidenced in Pf-infected RBCs, induced L-arginine-dependent NO production.

98 OS) and nitric oxide, produced mainly via an l-arginine-dependent process, contribute to the kinase a

99 Systemic L-arginine depletion following intravenous administratio

100 L-arginine-deprived T cells upregulated system L amino a

101 The parasite Giardia lamblia utilizes the L-arginine dihydrolase pathway to generate ATP from L-ar

102 ediated L-ornithine production compared with L-arginine directly imported from the extracellular mili

103 The importance of l-arginine during infection is supported by the finding

104 cells in G1, and this effect is mediated by l-arginine elimination rather than metabolite generation

105 ion, and inhibition of NO by N(G)-monomethyl-L-arginine enhanced intracellular survival of Mtb.

106 Pre-treatment with L-arginine enhances the ISCs pool and protects the gut i

107 ine cycle, because it provides the substrate L-arginine for subsequent NO synthesis by inducible, end

108 expressing MPhis preferred L-citrulline over L-arginine for the promotion of antimycobacterial activi

109 at shifted towards tetramers upon binding of L-arginine for the XcNAGS-K.

110 ng effect of Arg1 deletion was reduced by an l-arginine-free diet, but rescued by simultaneous deleti

111 , including N-alpha-(1-deoxy-D-fructos-1-yl)-L-arginine (FruArg).

112 with single nucleotide polymorphisms in the L-arginine:glycine amidinotransferase (AGAT) gene (P<2.1

113 ep process: L-arginine (L-Arg) --> N-hydroxy-L-arginine --> citrulline + NO.

114 tion following intravenous administration of l-arginine hydrolyzing enzymes has been shown to selecti

115 n to give ethylene is promoted by binding of l-arginine in a nonoxidized conformation and of 2-oxoglu

116 ll co-cultured models to clarify the role of L-arginine in ISC function.

117 stimulation or intraperitoneal injection of l-arginine in mice with deletion of interleukin (IL)12B,

118 a significant decrease in the NOS substrate l-arginine in plasma from CRPS patients, suggesting redu

119 dimethylarginine (ADMA) and N(G)-monomethyl-l-arginine, in tumor-bearing mice compared with control

120 L-arginine increased thermal stability of the NAGS-K fro

121 d the clinically compatible basic amino acid L-arginine increases in vitro planktonic and biofilm sus

122 is accompanied by minimal lung injury, while L-arginine induced extremely severe pancreatic injury in

123 21 deficiency protects against caerulein- or L-arginine-induced acute pancreatitis in mice.

124 Similar results occurred in mice with L-arginine-induced AP.

125 In addition, GW eliminated L-arginine-induced enhancement of Ca(2+) oscillations, p

126 iminates ACh-induced Ca(2+) oscillations and L-arginine-induced enhancement of Ca(2+) signaling in mo

127 Similar results were obtained using an l-arginine-induced model of AP.

128 of cyclophilin D with ATP synthase mediates L-arginine-induced pancreatitis, a model of severe AP th

129 r, in the pancreas of mice with cerulean- or L-arginine-induced pancreatitis, and in an oncogenic Kra

130 cids was between the extent of caerulein and L-arginine induction, with obvious inflammatory cells in

131 environmental) and endogenous (biosynthetic) L-arginine influence biofilm formation by P. putida thro

132 BH(4), L-arginine, or BH(4) plus L-arginine inhibited eNOS monomerization.

133 L-arginine inhibits NAGS in bacteria, fungi, and plants

134 ynthesized endogenously by the conversion of l-arginine into citrulline through nitric oxide synthase

135 Arginase 1 (Arg1), which converts l-arginine into ornithine and urea, exerts pleiotropic i

136 cells (e.g., endothelial cells) and converts l-arginine into ornithine and urea.

137 In this response, l-arginine is decarboxylated to agmatine, thereby consum

138 We find that exogenous L-arginine is essential for ISCs proliferation and intes

139 The third metabolic fate of L-arginine is the generation of creatine that acts as a

140 intra-arterial infusion of N(G) -monomethyl-L -arginine (L -NMMA) into the common femoral artery in

141 intra-arterial infusion of N(G) -monomethyl-L -arginine (L -NMMA) to inhibit nitric oxide synthase (

142 oxide (NO) synthesis via a two-step process: L-arginine (L-Arg) --> N-hydroxy-L-arginine --> citrulli

143 -Menten constant (K(M)(app)) derived from an L-arginine (L-Arg) calibration curve of 1.27 +/- 0.29 mM

144 hile also catalyzing the C5 hydroxylation of l-arginine (l-Arg) driven by the oxidative decarboxylati

145 tic depletion of the nonessential amino acid l-Arginine (l-Arg) in patients with cancer by the admini

146 c activity, as measured by the conversion of L-arginine (L-Arg) into L-citrulline, was augmented in l

147 more, the generated acidic H2 O2 can oxidize l-Arginine (l-Arg) into NO for enhanced gas therapy.

148 Increased metabolism of l-Arginine (l-Arg), through the enzymes arginase 1 and N

149 transporter of the semi-essential amino acid L-arginine (L-Arg), which has been implicated in wound r

150 urea moiety constructed from N(omega)-methyl-l-arginine (l-NMA) by the multi-domain metalloenzyme Szn

151 a intra-arterial infusion of N(G)-monomethyl-L-arginine (L-NMMA).

152 ic oxide synthase inhibitor N(G) -monomethyl-l-arginine (l-NMMA, 5 mg kg(-1) bolus & subsequent 50 mu

153 n sites: (i) control; (ii) 10 mm N(G) -nitro-l-arginine (l-NNA), a non-specific NOS inhibitor; (iii)

154 the nitric oxide synthase inhibitor N-nitro-l-arginine (l-NNA, 200 mum) and in nNOS-knockout (KO) mo

155 e nitric oxide synthase inhibitor N(G)-nitro-l-arginine (l-NNA; 100 mum) to block purinergic and nitr

156 on (Control), 400 nm ET-1, 10 mm N(G) -nitro-l-arginine (l-NNA; a NOS inhibitor) or a combination of

157 ginase-nitric oxide pathway (N(G)-monomethyl l-arginine [l-NMMA] monoacetate) reversed the inhibitory

158 luconazole) and NO synthase (N(G)-monomethyl-l-arginine [L-NMMA]).

159 mycobacteria-infected murine MPhis supplied L-arginine, L-citrulline, or both amino acids.

160 This study examined the ability of l-arginine, l-cysteine and l-methionine, to inhibit post

161 L-Arginine, L-glutamine, DL-histidine, malate, and DL-or

162 udes l-asparagine, l-glutamine, l-threonine, l-arginine, l-glycine, l-proline, l-serine, l-alanine, a

163 experiments were conducted with amino acids (l-arginine, l-histidine, and glycine) that are represent

164 Proline, L-arginine, L-histidine, L-isoleucine, and tryptophan we

165 In most cells, cationic amino acids such as l-arginine, l-lysine, and l-ornithine are transported by

166 ve; no evidence was found for the binding of L-arginine, L-ornithine, L-2,4-diaminobutyric acid, and

167 .29-0.59], P = 0.01) and lower median plasma l-arginine (late onset, 52.3 [IQR, 43-61] compared with

168 ated infection, gentamicin supplemented with L-arginine led to complete, long-lasting eradication of

169 The L-arginine level and the L-arginine to ADMA ratio (a mea

170 aria, compared with healthy controls (median L-arginine level, 65, 66, and 98 micromol/mL, respective

171 Day0 values correlated with plasma L-arginine levels (r = 0.69; p = 0.01) and weakly with p

172 this effect correlated strongly with plasma L-arginine levels (r = 0.89; p < 0.0001).

173 tential of novel bi-ligand (transferrin-poly-l-arginine) liposomal vector for delivery of desired gen

174 nhanced NO activity, because N(G)-monomethyl-l-arginine markedly blunted the flow response to obestat

175 Supplementation with L-arginine may be an effective measure to counteract the

176 ity (percent constriction to N(G)-monomethyl-l-arginine [mean (SEM) wild type 106% (30%); hIGFREO 48%

177 rulline (800, 1600 mum) rescued NOx when the l-arginine media concentration was 25 mum but failed to

178 Under reduced l-arginine media conditions, HBECs treated with l-citrul

179 een associated with endothelial dysfunction (L-arginine), metabolic acidosis (alanine and lactate), a

180 is reliant on inducible NO synthase-mediated L-arginine metabolism in macrophages (MPhis).

181 Targeting l-arginine metabolism is intriguing, considering this am

182 Consequently, l-arginine metabolism may serve as a target for clinical

183 ous studies have linked alterations in local L-arginine metabolism, principally mediated by the enzym

184 DDAH1 and MED23/Arg1 in regulating ADMA and l-arginine metabolism, respectively, and identify a nove

185 ization is accompanied by drastic changes in L-arginine metabolism.

186 ut rescued by simultaneous deletion of other l-arginine-metabolizing enzymes, such as Arg2 or Nos2, d

187 N(G)-nitro-l-arginine methyl ester (100 mumol/L) or a protease-acti

188 base material to examine the feasibility of L-Arginine methyl ester (L-AME) functionalized material

189 The NOS inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) administered after blas

190 and mechanism of action of Mb on N(G)-Nitro-L-arginine Methyl Ester (L-NAME) and Deoxycorticosterone

191 Molsidomine or NG-nitro-L-arginine methyl ester (L-NAME) or saline were applied

192 We report in this article that L-N(G)-nitro-L-arginine methyl ester (L-NAME) pretreatment blocked, w

193 tors was reduced in the presence of NG-nitro-L-arginine methyl ester (L-NAME), a general inhibitor of

194 bolished by application of either N(G)-nitro-l-arginine methyl ester (l-NAME), an inhibitor of NO syn

195 inhibition in cancer cells using N(G)-nitro-l-arginine methyl ester (l-NAME), we demonstrate that pa

196 However, pretreatment of VEC with nitro-L-arginine methyl ester (L-NAME), while inhibiting the r

197 e nitric oxide synthase using N(omega)-nitro-L-arginine methyl ester (L-NAME)-recapitulates the numer

198 th the constitutive NOS inhibitor N(G)-nitro-l-arginine methyl ester (L-NAME).

199 ated NOS small molecule inhibitor N(G)-nitro-L-arginine methyl ester (l-NAME).

200 xide (NO) synthase inhibitor N(omega) -nitro-l-arginine methyl ester (P > 0.05), indicating that lowe

201 ore and during NO inhibition (N(omega)-nitro-l-arginine methyl ester [L-NAME]).

202 N(omega)-Nitro-L-arginine methyl ester and 1H-[1,2,4]-oxadiazolo-[4,3-a

203 clearance, whereas infusion of Nomega-nitro-L-arginine methyl ester and a high dose of aminoguanidin

204 e presence of the NOS inhibitors, N(G)-nitro-L-arginine methyl ester and aminoguanidine; in addition,

205 tion by the NO synthase inhibitor N(G)-nitro-l-arginine methyl ester and the superoxide dismutase mim

206 NOS inhibitor N(G)-nitro-L-arginine methyl ester attenuated the endothelial barri

207 reated with ceramide, whereas N(omega)-nitro-l-arginine methyl ester had no effect.

208 administration of the NOS inhibitor N-nitro-L-arginine methyl ester hydrochloride (L-NAME), includin

209 nsive challenges using either N(omega)-nitro-L-arginine methyl ester hydrochloride (L-NAME)/high salt

210 d Ringer's (control); (2) 20 mm Nomega-nitro-l-arginine methyl ester hydrochloride (non-selective NOS

211 e of DTT and the NO inhibitor N(omega)-nitro-L-arginine methyl ester hydrochloride, the ability of CO

212 The eNOS inhibitor N(G)-Nitro-l-arginine methyl ester mimicked anti-VEGF/VEGFR drugs,

213 he inhibitory effects of ADMA and N(G)-nitro-l-arginine methyl ester on inducible NOS (macrophages) a

214 Glibenclamide and N(G)-nitro-l-arginine methyl ester partially blocked the effect, in

215 N(omega)-nitro-l-arginine methyl ester reduced vasodilation to flow in

216 difluoro-2-phenyl-1H-indol-3-yl)-1-oxobutyl]-L-arginine methyl ester trifluoroacetate) in M1 ipRGCs.

217 urther, the inhibition of eNOS (l-N(G)-nitro-L-arginine methyl ester), Mas (A-779), and SIRT1 (nicoti

218 with a nonselective inhibitor (Nomega-nitro-L-arginine methyl ester).

219 gistically amplified by co-addition of tosyl-l-arginine methyl ester, a small molecule that blocks th

220 (Ca)) channels, respectively, and N(G)-nitro-L-arginine methyl ester, an inhibitor of nitric oxide sy

221 4 expression was abrogated by N(omega)-nitro-l-arginine methyl ester, an inhibitor of NOS.

222 ind that the small-molecule inhibitor, tosyl-l-arginine methyl ester, preferentially suppresses APC/C

223 oxide (NO) synthase inhibitor l-N (G)-nitro-l-arginine methyl ester, while iontophoresis of the NO d

224 thionylation and eNOS-derived N(omega)-nitro-L-arginine methyl ester-sensitive superoxide formation i

225 c oxide synthase (eNOS) inhibitor N(G)-nitro-L-arginine methyl ester.

226 hat was abrogated by administration of nitro-l-arginine methyl ester.

227 f nitric oxide synthase with N(omega) -nitro-l-arginine methyl ester.

228 the nitric oxide synthase inhibitor NG-nitro-l-arginine methyl ester.

229 L-NAME (N(omega)-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor

230 Nomega-nitro-L-arginine-methyl-ester (L-NAME) or placebo was administ

231 Treatment with l-arginine modestly lowers blood pressure of collectrin

232 ric oxide synthase inhibitor N(G)-monomethyl-L-arginine, monoacetate salt (L-NMMA).

233 locked by the iNOS inhibitor N(G)-monomethyl-l-arginine, monoacetate salt, and 3) RA-DCs derived from

234 ll binding and entry using galactose sugars, l-arginine, neutralizing membrane protein antibodies, or

235 ne through the intermediate N(omega)-hydroxy-L-arginine (NHA), producing nitric oxide, an important m

236 , NO production increased in the presence of l-arginine (nitric-oxide synthase [NOS] substrate), and

237 -selective NOS inhibitor); (3) 5 mm N-propyl-l-arginine (nNOS inhibitor); and (4) 10 mm N(5)-(1-imino

238 Naturally occurring N(omega)-hydroxy-l-arginine (NOHA, 1) is the best substrate of NO synthas

239 N-Hydroxy-Nor-L-arginine (Nor-NOHA) was used as an arginase inhibitor.

240 rochloride, arginase inhibitor N-hydroxy-nor-l-arginine (nor-NOHA), and blocking antibodies for IL-4R

241 -boronohexanoic acid (ABH) and N-hydroxy-nor-l-arginine (nor-NOHA).

242 nction, little is known about the effects of L-arginine on intestinal stem cells (ISCs).

243 n signaling pathway, mediates the effects of L-arginine on ISCs function.

244 Different effects of L-arginine on oligomerization of NAGS may have implicati

245 ght the beneficial effects of spermidine, or l-arginine, on gut immunity by promoting Treg cell devel

246 tion of malarial-parasite-infected mice with L-arginine or L-citrulline reduced levels of ileal trans

247 BH(4), L-arginine, or BH(4) plus L-arginine inhibited eNOS mono

248 ition of this enzyme or supplementation with L-arginine overrides immunosuppression.

249 gatively with arginase-1 and positively with l-arginine (P = .001).

250 were significantly attenuated by monomethyl-l-arginine (P<0.01 versus placebo).

251 ity, 2) the Arg-1 inhibitor N(w)-hydroxy nor-l-arginine partially reversed suppression, and 3) the su

252 Because the L-arginine pathway is essential for G. lamblia survival

253 They acted at least partly through the l-arginine pathway.

254 Rather, their contribution to global L-arginine pools appears to determine changes in c-di-GM

255 tives (trehalose, glycine betaine, mannitol, L-Arginine, potassium citrate, CuCl(2), proline, xylitol

256 L-Arg reaction but also during the N-hydroxy-L-arginine reaction.

257 d circulating glucagon levels and attenuated l-arginine-stimulated glucagon secretion both in vivo an

258 nt of the mNAGS increased in the presence of L-arginine suggesting smaller hydrodynamic radius due to

259 However, L-arginine supply can be restricted by arginase activity

260 Eliminating l-arginine synthesis from l-citrulline in myeloid cells

261 tandem mass spectrometry, we determined that L-arginine synthesized from L-citrulline was less effect

262 h as the peritoneal injections of caerulein, L-arginine, the retrograde infusion of sodium taurochola

263 ircumvent this by converting L-citrulline to L-arginine, thereby resupplying substrate for NO product

264 itates the export of agmatine in exchange of l-arginine, thus providing substrates for further remova

265 ate-onset asthma phenotype, plasma ratios of L-arginine to ADMA may explain the inverse relationship

266 The L-arginine level and the L-arginine to ADMA ratio (a measure of L-arginine bioava

267 icromol/mL, respectively [P = .0001]; median L-arginine to ADMA ratio, 115, 125, and 187, respectivel

268 ively; P = .018) and was associated with the L-arginine to ADMA ratio.

269 f a high-energy phosphoryl group from ATP to l-arginine to form phosphoarginine, which is used as an

270 nt of the guanidine group of N(omega)-methyl-L-arginine to generate an N-nitrosourea product.

271 Given that intravenous administration of L-arginine to human patients is well tolerated, combined

272 ated isoforms that catalyze the oxidation of L-arginine to L-citrulline and the important second mess

273 e synthase (NOS) catalyzes the conversion of l-arginine to l-citrulline and the second messenger nitr

274 ii) The H2O2-mediated oxidation of N-hydroxy-L-arginine to L-citrulline by a series of hemin/G-quadru

275 e in BH4 synthesis), and NOS activity ((14)C L-arginine to L-citrulline conversion) were measured by

276 e synthase (NOS) catalyzes the conversion of L-arginine to L-citrulline through the intermediate N(om

277 synthesizes nitric oxide (NO) by converting L-arginine to L-citrulline, is highly concentrated in pl

278 required for the synthesis and channeling of L-arginine to nitric oxide synthase (NOS) for nitric oxi

279 The breakdown of L-arginine to ornithine and urea by host arginase suppor

280 Arg1) and nitric oxide synthases compete for l-arginine to produce either polyamines or nitric oxide,

281 Moreover, addition of exogenous L-arginine to the cultures increased deformability of bo

282 plementation of spermidine, or its precursor l-arginine, to assess the frequency and total numbers of

283 decarboxylase, diverting the iNOS substrate l-arginine toward the synthesis of polyamines.

284 We also administered primed infusions of l-arginine uniformly labeled with (13)C(6) and (15)N(4)

285 ian cells produces higher levels of NO. from l-arginine upon infections to eliminate pathogens.

286 Furthermore, collectrin directly regulates l-arginine uptake and plasma membrane levels of CAT1 and

287 oxide synthase (asymmetrical DMA [ADMA]) and l-arginine uptake into the cell (ADMA and symmetrical DM

288 nd closure and increased cell proliferation, L-arginine uptake, CAT1 and CAT2 protein levels, total p

289 s cell proliferation, scratch wound closure, L-arginine uptake, cationic amino acid transporter activ

290 roughout the vasculature, where it regulates L-arginine uptake.

291 Arginase-II (Arg-II), the type-II L-arginine-ureahydrolase, is highly expressed in pancrea

292 Most animals produce NO from L-arginine via a family of dedicated enzymes known as NO

293 endogenous NO production from the amino acid l-arginine, via nitric oxide synthase (NOS) enzymes, res

294 ort systems to the response to environmental L-arginine was also studied.

295 The effects of l-arginine were blocked by bath application of l-NAME (2

296 treated with the iNOS inhibitor N-monomethyl-l-arginine were largely unable to resolve genital tract

297 /locus of cross-over P strategy; cerulein or L-arginine were used to induce AP.

298 -citrulline (co-product of NO synthesis from L-arginine), which were affected by NOS inhibitors confi

299 mmetric dimethyl arginine (ADMA) relative to L-arginine, which can lead to greater nitric oxide synth

300 by KCl and the addition of flavor enhancers (l-arginine, yeast and oregano extract) on probiotic Prat